Monoclonal antibody (mAb)-based cancer therapy

Monoclonal antibody (mAb)-based cancer therapy

Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more effective.

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections

More than 150 arboviruses belonging to different families are known to infect humans, causing endemic infections as well as epidemic outbreaks. Effective vaccines to limit the occurrence of some of these infections have been licensed, while for the others several new immunogens are under development mostly for their improvements concerning safety and effectiveness profiles. On the other hand, s...

Protein A Affinity Column for Monoclonal Antibody (MAb) Titer Analysis

Monoclonal Antibody-based Therapy for Eosinophilic Oesophagitis

Eosinophilic oesophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the oesophagus. Eosinophils are major pro-inflammatory cells thought to make a significant contribution to allergic diseases that affect the upper and lower airways, skin, and gastrointestinal tract. Type 2 cytokines such as interleukin (IL)-5 and IL-13 are central to ...

Minimising non-human primate use in monoclonal antibody (mAb) development

the changing environment of monoclonal antibody (mAb) development is impacting on the cost of drug development and the use of experimental animals, particularly non-human primates (NHPs). the drive to reduce these costs is huge and involves rethinking and improving nonclinical studies to make them more efficient and more predictive of man. As our knowledge base on mAbs expands, the information ...